<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="336880">
  <stage>Registered</stage>
  <submitdate>2/05/2011</submitdate>
  <approvaldate>3/05/2011</approvaldate>
  <actrnumber>ACTRN12611000451909</actrnumber>
  <trial_identification>
    <studytitle>Childhood obesity and propofol infusion</studytitle>
    <scientifictitle>The pharmacokinetics and pharmacodynamics of propofol infusion in obese children.</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Childhood obesity</healthcondition>
    <conditioncode>
      <conditioncode1>Anaesthesiology</conditioncode1>
      <conditioncode2>Other anaesthesiology</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Diet and nutrition</conditioncode1>
      <conditioncode2>Obesity</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Pharmacokinetic study involving propofol infusion and arterial blood sampling
Target controlled infusion of propofol utilisng the Kataria pharmacokinetic dataset and titrating target plasma concentration to achieve a bispectral index between 40 and 60.
There will be  both obese (50) and non-obese (10) groups.</interventions>
    <comparator>Non-obese children</comparator>
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Arterial blood concentration of propofol vs time with subsequent pharmacokinetic analysis utilisng mixed effect modelling to assess the impact of obesity on propofol infusion pharmacokinetics</outcome>
      <timepoint>Sampling at 2, 5, 10 and 15 minutes and the 15 minutely until cessation of infusion.
Sampling will then occur at 2, 5, 10, 15 minutes and then 15 minutely following cessation until removal of the arterial sampling line.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Bi spectral index vs arterial propofol concentration
Continuous BIS recording will be related to actual arterial concentration at the measured time points.
This will enable construction of a BIS response curve as well as estimation of the time to peak effect.</outcome>
      <timepoint>Continuous until cessation infusion</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Children 5 - 15 years old
Obese defined as by the age and sex corrected BMI figures of Cole
Surgical or investigative procedure requiring general anaesthetic
Control group will include ten 5-15 year old normal range BMI patients recieving general anaestehtic</inclusivecriteria>
    <inclusiveminage>5</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>15</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Cardiopulmonary bypass and liver transplantation.
Propofol or propofol emulsion component allergy</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Pharmacokinetics / pharmacodynamics</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>1/11/2011</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>60</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Auckland City Hospital</primarysponsorname>
    <primarysponsoraddress>Private Bag 92 024
Auckland Mail Centre
Auckland 1142</primarysponsoraddress>
    <primarysponsorcountry>New Zealand</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>A+ charitable trust</fundingname>
      <fundingaddress>A+ charitable trust
Private Bag 92 024
Auckland Mail Centre
Auckland 1142</fundingaddress>
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Society for paediatic anaesthesia in Australia and New Zealand</fundingname>
      <fundingaddress>PO Box 180
Morisset 
NSW 2264
Australia</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>A pharmacokinetic and pharmacodynamic study aiming to investigate the impact of childhood obesity on propofol infusion. General anaesthesia will be carried out with propofol infusion (Using Kataria PK model). Arterial blood sampling will determine pharmacokinetics and BIS monitoring will determine pharmacodynamics. Pharmacokinetic analysis will focus on how best to account for obesity in children recieving propofol infusion.</summary>
    <trialwebsite>n/a</trialwebsite>
    <publication>n/a</publication>
    <ethicsreview>Not yet submitted</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Northern  X regional committee</ethicname>
      <ethicaddress>Private Bag 92-522
Wellesley St
Auckland 1141</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate>14/06/2011</ethicsubmitdate>
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>James Houghton</name>
      <address>Department of Anaesthesia
Starship Children's Hospital
Private Bag 92 024
Auckland Mail Centre
Auckland 1142</address>
      <phone>+6493670000</phone>
      <fax />
      <email>jamesho@adhb.govt.nz</email>
      <country>New Zealand</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>James Houghton</name>
      <address>Department of Anaesthesia
Starship Children's Hospital
Private Bag 92 024
Auckland Mail Centre
Auckland 1142</address>
      <phone>+6493670000</phone>
      <fax />
      <email>jamesho@adhb.govt.nz</email>
      <country>New Zealand</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>James Houghton</name>
      <address>Department of Anaesthesia
Starship Children's Hospital
Private Bag 92 024
Auckland Mail Centre
Auckland 1142</address>
      <phone>+6493670000</phone>
      <fax />
      <email>jamesho@adhb.govt.nz</email>
      <country>New Zealand</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>